Theravance Biopharma TBPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.78M+2.2% | $107.46M+33.8% | $80.33M+4.0% | $77.21M+18.3% | $65.27M+1.4% | ||
| $31.79M-15.0% | $37.41M-5.3% | $39.51M-2.8% | $40.66M+1.3% | $40.13M+6.6% | ||
| $73M-0.9% | $73.65M0.0% | $73.63M+2.0% | $72.18M+1.9% | $70.8M+2.4% | ||
| $108.43M-2.4% | $111.07M-1.8% | $113.14M-1.1% | $114.4M-0.9% | $115.44M+3.7% | ||
| $108.43M-2.4% | $111.07M-1.8% | $113.14M-1.1% | $114.4M-0.9% | $115.44M+3.7% | ||
| $1.35M+137% | -$3.6M+89.0% | -$32.81M+11.8% | -$37.2M+25.9% | -$50.18M-6.9% | ||
| 1.2%+4.6pp | -3.4%+37.5pp | -40.9%+7.3pp | -48.2%+28.7pp | -76.9%-4.0pp | ||
| —— | $2.46M-2.4% | $2.52M-2.2% | $2.58M+0.7% | $2.56M+0.5% | ||
| $12.25M+20.4% | $10.17M+36.8% | $7.44M+57.8% | $4.72M+7.5% | $4.39M-10.1% | ||
| $136.92M+5.9% | $129.25M+174% | $47.24M+17.9% | $40.08M+183% | -$48.35M-8.4% | ||
| $22.37M-4.2% | $23.35M+30.5% | $17.9M-33.8% | $27.05M+171% | $9.98M-15.4% | ||
| $114.54M+8.2% | $105.9M+261% | $29.34M+125% | $13.03M+122% | -$58.33M-3.4% | ||
| 104.3%+5.8pp | 98.5%+62.0pp | 36.5%+19.7pp | 16.9%+106pp | -89.4%-1.7pp | ||
| $2.20+8.4% | $2.03+256% | $0.57+138% | $0.24+120% | -$1.18-2.6% | ||
| $2.26+8.1% | $2.09+260% | $0.58+132% | $0.25+121% | -$1.18-2.6% | ||
| 205.4M+0.8% | 203.8M+1.3% | 201.2M+1.4% | 198.3M+1.0% | 196.3M+0.7% | ||
| 202.3M+0.8% | 200.7M+0.7% | 199.3M+0.7% | 197.8M+0.7% | 196.3M+0.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.25M+20.4% | $10.17M+36.8% | $7.44M+57.8% | $4.72M+7.5% | $4.39M-10.1% | ||
| $109.78M+2.2% | $107.46M+33.8% | $80.33M+4.0% | $77.21M+18.3% | $65.27M+1.4% | ||
| $1.35M+137% | -$3.6M+89.0% | -$32.81M+11.8% | -$37.2M+25.9% | -$50.18M-6.9% | ||
| $2.94M+249% | -$1.98M+93.7% | -$31.17M+12.3% | -$35.52M+26.7% | -$48.49M-7.2% | ||
| $2.94M+249% | -$1.98M+93.7% | -$31.17M+12.3% | -$35.52M+26.7% | -$48.49M-7.2% | ||
| 2.7%+4.5pp | -1.8%+37.0pp | -38.8%+7.2pp | -46%+28.3pp | -74.3%-4.0pp | ||
| $1.35M+137% | -$3.6M+89.0% | -$32.81M+11.8% | -$37.2M+25.9% | -$50.18M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
